A new Talcum Powder lawsuit has been added to the nearly 5,500 existing talcum powder cases filed against giant conglomerate Johnson & Johnson across the country. This case has been filed in Connecticut by the family of a deceased woman who suffered ovarian cancer allegedly caused by J&J's product. MDL 2738 (In re Johnson & Johnson Talcum Powder Products Marketing, Sales Practices and Products Liability Litigation) was formed in October 2016 before Hon. Freda L. Wolfson, U.S.D.J., in the U.S. District for New Jersey which involved centralization of the federally filed cases. Talcum Lawsuits are also filed in state courts in Missouri, New Jersey, and California.
Essure lawsuits filed against Bayer in various federal and state throughout the nation, witnessed the addition of another lawsuit filed by at least fifty plaintiffs from Texas, Florida, Illinois, and other states alleging that Essure birth implant caused severe injuries.
Abilify Lawsuits are witnessing a steep increase in the number of cases filed against drug makers Otsuka Pharmaceutical Co. and Bristol-Myers Squibb Company alleging serious financial damages from compulsive gambling addiction losses. A Louisiana woman has filed the latest lawsuit claiming compensation for the losses she incurred from the gambling addiction as a direct result of her Abilify prescription. Claims against the drug makers include failure to warn the public in spite of being aware of the link between compulsive behavior development and Abilify. The Abilify lawsuits are centralized in the U.S. District Court for the Northern District of Florida, under MDL No. 2734 (In Re: Abilify Compulsive Behavior Products Liability Litigation), in October 2016, before Chief Judge M. Casey Rodgers. Trials are expected to begin by the end of 2017.
MDL No. 2804 (In Re: National Prescription Opiate Litigation), set for a JPML consolidation hearing November 30, 2017, is joined by a new group of plaintiffs against Opioid manufacturers, wholesalers, and distributors; these include unions and locals that would make it a proliferating MDL, if approved.